About Us

In today’s ever-changing landscape of drug development, evidence-based medicine, and best practices, a strong foundation of knowledge and ongoing education are essential. As a trusted expert in the field, I can provide you with the guidance you need to keep up with new medication innovations and usage.

Whether you’re facing a complex pharmacy-related case or simply seeking clarity on multiple medications, I’m here to help. When you require a detailed explanation of drug-related topics or understanding a pharmacist’s standard of care, it’s time for a targeted discussion. With years of experience as a pharmacy expert, I’ve aided numerous professionals with document evaluations, with or without a written opinion.

My micro-consulting services allow you to discuss your questions without any obligation, and our conversation will determine whether you need an expert, support for your case, or general knowledge of pharmacy practice. If you’re in need of an expert witness, clinical pharmacist, or consulting services, look no further. With my extensive clinical and practical experience working on various pharmacy-legal cases, I can provide you with a deeper understanding of complex drug-related topics.

Explore my website and discover the services and expertise available to you. Alternatively, feel free to contact me by phone or email, and I’ll be happy to answer any questions you may have. Attorneys, pharmaceutical companies, insurance companies, and individuals can all benefit from the pharmacy consulting services provided by Grant Clinical Consulting. With my help, you can achieve your goals and outcomes with confidence.

Thank you for visiting,

Dr. Wayne H. Grant

Dr. Wayne H. Grant: Bridging Expertise in Clinical Practice, Education, and Leadership Across Diverse Healthcare Settings

Since 1990, Dr. Wayne H. Grant has been a registered pharmacist in good standing in the State of Ohio. He obtained his Bachelor of Pharmacy degree from Ohio Northern University, Ada, Ohio, in 1990, his Doctor of Pharmacy degree from the University of Florida, Gainesville, Florida, in 2007, and an MBA from Kent State University in 2016. Dr. Grant’s clinical practice is in hospice, palliative care, and eldercare, focusing on disease state management in numerous areas.

Preparing and delivering educational classes to physicians, nurses, and other healthcare professionals on pain management, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, dementia, and cancer-related problems is a significant part of my responsibilities. Sitting on multiple committees, including the pharmacy and therapeutics, motor neuron disease, and quality, becomes essential to promote the appropriateness of medical interventions.   Speaking on educational topics within our agency and to health-systems outside our agency allows for a collaboration of care that benefits our clients.

Dr. Grant’s expertise in hospital, long-term, institutional, infusion, and retail practice demonstrates an extensive understanding of the various pharmacy sectors.  Dr. Grant has delivered local, state, national, and international speaking programs reflecting the fundamental practice of pharmacy. As a peer reviewer for the American Journal of Health-System Pharmacy, he provides feedback on articles that will determine future drug therapies.

Dr. Grant’s clinical practice, management, and education culminate in his current understanding of the pharmacy profession and the high standards we hold.

MISSION STATEMENT

Provide a service based on the fundamental practice of pharmacy. Clients will become knowledgeable of specific medication choices through review, interpretation, and application of evidence-based medicine. Integrating the latest research and practice standards will aid in achieving this objective. The cornerstone of this mission is providing a transparent, open, and honest discussion of the individual circumstance while maintaining respect for the client’s privacy and choice regardless of the opinions and recommendations offered.

EXCERPTS

Ketamine is FDA-approved as a rapid-acting IV dissociative general anesthetic. There has been increased interest in its off-label use for pain control, administered via various routes.

Cold storage transportation

The stability of drugs being stored can be affected by transportation. Maintaining a temperature between 2 to 8 degrees Celsius is necessary for cold chain products, while frozen products.

Biosimilars

A biosimilar is a highly similar biological product with no clinically meaningful differences from an existing FDA-approved reference product. “No clinically meaningful differences“ include the..

Compounding

Compounding is an essential aspect of the pharmacy profession, encompassing sterile and nonsterile preparation of medications. United States Pharmacopeia (USP) Chapters 795.

Nausea & Vomiting

The mechanism of delay-nausea (>24hours) involves stimulation of neuroreceptors other than serotonin. Dopamine mediations dominate this type of nausea.

Methadone

Methadone, an agonist of mu and delta and an antagonist at the NMDA (N-methyl-D-aspartate) receptor, offers a unique treatment option. Pain negatively affects the NMDA

Overall Considerations

The complexity of drug therapy requires an expert capable of reviewing, writing, and supporting attorneys in the understanding of drug therapy. Law firms seek medication management experts in negligence cases and antitrust, reimbursement, manufacturing, and policy support. If your firm does not have a pharmacist available for oversight and litigation support or needs one, perhaps this is the time to call.

Having a complete and current understanding of drug therapy is achieved through academic learning, teaching, and clinical responsibilities.  My experience in long-term care, institutional (prison), infusion, hospice, and retail practice strengthened my ability to decipher the medical management of patients transitioning through different healthcare settings.

The ultimate goal is to deliver a clear and concise summary of complex pharmacy situations through open and honest dialogue. If you require my services, my complete CV and fee schedule information can be available upon request.

Frequently Asked Questions

Yes.  Whether it is workflow assessment, regulatory oversight, or clinical services, GCC will evaluate, review, and report any findings and make recommendations for correction or improvements.

Yes/No.  If the organization prefers onsite consultative services, I will establish timelines for such services and coordinate travel, meetings, and outcome delivery with the organization.

Yes.  Although the quality of the services doesn’t change, the dedication of time to the organization does.

Yes/No.  If the organization wants a written report of findings and recommendations, I will provide this.  However, if the organization does not want this and prefers an oral report only, this can be arranged.

Yes.  If you or your loved one wants a review of the drugs that are currently prescribed or supplements being taken, with the purpose of understanding the medications, consider if negative side effects are due to the drugs, or recommend alternative choices.

Yes.  GCC can make written recommendations to the prescribers, such as physicians, with the consent of the patient or responsible party.  

No.  The services are billed 100% to the individual or responsible party.

Yes.  Although the quality of the services doesn’t change, the dedication of time to the patient and/or family does.

Yes.  For an individual, four hours is the minimum number of hours billed.  

No.  Each patient is different, and their past medical history and medication records are varied.  

Yes.  To learn more, e-mail or call GCC for a free initial conversation.  If you want to proceed, a fee schedule will be sent out for your review.

Contact Us

Ketamine

Ketamine is FDA-approved as a rapid-acting IV dissociative general anesthetic.  There has been increased interest in its off-label use for pain control, administered via various routes.  This Fast Fact reviews the use of ketamine in palliative care, primarily for analgesia.

As an anesthetic, ketamine is given IV or IM.  For pain, the parenteral solution can be delivered at much lower doses by oral, intranasal, transdermal, rectal, and subcutaneous routes. The onset of analgesia is 15-30 minutes; the duration of action is 15 minutes to 2 hours, possibly longer orally.  A greater portion of ketamine is metabolized to a breakdown product with less affinity for NMDA receptors (norketamine) when taken orally versus IV.  It is not yet clear if this reduces the analgesic properties of oral ketamine in a clinically significant way.

Cold storage transportation

The stability of drugs being stored can be affected by transportation. Maintaining a temperature between 2 to 8 degrees Celsius is necessary for cold chain products, while frozen products must be kept below minus 10 degrees Celsius. An “ultra-cold chain” may sometimes require holding temperatures below minus 80 degrees Celsius.  Pharmacies commonly handle the packaging and delivery of these drugs, as they are equipped to manage their storage and transportation needs.

Biosimilars

A biosimilar is a highly similar biological product with no clinically meaningful differences from an existing FDA-approved reference product. “No clinically meaningful differences“ include the safety, efficacy, purity, and potency of the drugs, which has typically been demonstrated by pharmacokinetic (PK) and pharmacodynamic (PD) studies.

Compounding

Compounding is an essential aspect of the pharmacy profession, encompassing sterile and nonsterile preparation of medications. United States Pharmacopeia (USP) Chapters 795 and 797 regulate nonsterile and sterile compounding, respectively.  It allows for personalized dosages to be tailored to individual patients, making it a crucial component of drug delivery. The Food and Drug Administration (FDA) has divided compounded products into two categories: 503A and 503B. Medications prepared for specific patients based on orders from a licensed prescriber fall under 503A, which is considered traditional compounding. Meanwhile, 503B outsourcing facilities are subject to more stringent regulations. These facilities can compound and distribute non-patient-specific preparations, unlike those falling under 503A. Most hospitals and mainstream retail compounding pharmacies operate under 503A.

Nausea & Vomiting

The mechanism of delay-nausea (>24hours) involves stimulation of neuroreceptors other than serotonin. Dopamine mediations dominate this type of nausea. This leads to the benefit seen with phenothiazines (chlorpromazine, promethazine) and butyrophenone (haloperidol). The use of 5HT-3 antagonists, such as ondansetron, is not beneficial in this phase of emesis control as it lacks dopaminergic activity. The use of other drugs, such as dexamethasone, metoclopramide, droperidol, and olanzapine, may provide relief.

Methadone

Methadone, an agonist of mu and delta and an antagonist at the NMDA (N-methyl-D-aspartate) receptor, offers a unique treatment option. Pain negatively affects the NMDA receptor through what is postulated as an interaction on the excitatory transmitters (glutamate and aspartate), resulting in central sensitization. Using an NMDA blocking agent is thought to reduce or interfere with the discharge threshold, making it less sensitive and able to restrain the transmittal of pain signals.